Capecitabine 150mg Tablet, Film Coated
Product Images NDC 72485-204

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine 150mg (NDC 72485-204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

72485204 2

Label for Capecitabine Tablets, USP 150 mg, film-coated oral tablets. The label indicates the product contains 60 tablets and is a cytotoxic agent. It includes directions to swallow tablets whole and not to crush or cut them. The label shows the NDC 72485-204-60 and the labeler as Armas Pharmaceuticals Inc.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Disease-free Survival (all Randomized Population)a (Fig 1)

A Kaplan-Meier survival curve comparing two treatment groups: 5-FU plus Leucovorin (dashed line) and Capecitabine (solid line). The X-axis represents months since randomization (0 to 96), and the Y-axis represents survival probability (0 to 1). The number of patients at risk over time is shown below the X-axis for each treatment group.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Overall Survival (all Randomized Population) (Fig 2)

A survival curve chart comparing two treatment groups: 5-FU plus Leucovorin and Capecitabine. The x-axis represents months since randomization, and the y-axis shows survival probability, depicting the survival trends over time for each treatment group.*

FDA Label Image

Figure 3 Kaplan-meier Curve For Overall Survival Of Pooled Data (studies 1 And 2) (Fig 3)

A Kaplan-Meier survival curve comparing two treatment groups: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine 1250 mg/sqm twice daily intermittent. The chart shows estimated probability on the y-axis versus time in days on the x-axis, highlighting survival over approximately 1500 days.*

FDA Label Image

Figure 4 Kaplan-meier Estimates For Time To Disease Progression Capecitabine And Docetaxel Vs Docetaxel (Fig 4)

A Kaplan-Meier survival curve graph showing estimated probability over time in days. It compares two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph includes annotations around median survival times of approximately 128 and 186 days for each group.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Survival Capecitabine And Docetaxel Vs Docetaxel (Fig 5)

A survival curve chart showing estimated probability over time in days for two groups: one treated with Docetaxel 100 mg/sqm every 3 weeks, and the other treated with Capecitabine 1250 mg/sqm twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks. The chart plots probability on the vertical axis against time on the horizontal axis up to 800 days, with marked points at approximately 351.5 and 442.0 days.*

FDA Label Image

Metabolic Pathway (Meta Pathway)

An enzymatic pathway diagram illustrating the metabolic conversion of Capecitabine through the actions of Carboxylesterase, Cyd deaminase, and dThdPase enzymes, resulting in intermediate metabolites 5'-DFCR and 5'-DFUR, and finally producing 5-FU (5-fluorouracil). Chemical structures are shown for each compound with arrows indicating the sequential enzymatic steps.*

FDA Label Image

Structural Formula (Structural Formula)

Chemical structure of the active ingredient Capecitabine, depicting its molecular arrangement including fluorine atom and other functional groups, consistent with the 150 mg oral tablet dosage form by Armas Pharmaceuticals Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.